Axsome Therapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule medicines and novel therapies targeting central nervous syst... Axsome Therapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule medicines and novel therapies targeting central nervous system disorders. The company focuses on conditions with limited treatment options, including depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. Axsome's approach includes fixed-dose combinations and reformulations designed to deliver differentiated therapeutic solutions. The company maintains a pipeline of clinical-stage CNS therapies addressing significant and growing markets. Founded in 2012 and headquartered in New York, New York, Axsome operates as a single business segment dedicated to developing and delivering innovative treatments for patients with underserved CNS conditions. The company has transitioned to commercializing its marketed products while advancing its pipeline of differentiated therapeutic candidates.Show lessShow more

Disclosures ESG Data Financial Data

Income Statement Balance Sheet Group Entities

Data not available

Group Entities data not yet covered for Axsome Therapeutics

We have not yet reviewed Axsome Therapeutics's disclosures for Group Entities data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Axsome Therapeutics's data?

Start your 30-day free trial to request a data review for Axsome Therapeutics.

Start Free Trial

Legal Center Contact Us

Axsome Therapeutics Inc

Group Entities data not yet covered for Axsome Therapeutics

Account Restricted